Skip to main
DHR

Danaher (DHR) Stock Forecast & Price Target

Danaher (DHR) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Danaher is a well-established and diversified manufacturing company with a strong focus on the life sciences and diagnostic industries. Recent divestitures have resulted in a streamlined and more focused portfolio, with the company's newest acquisition, Cytiva, demonstrating strong core revenue growth in the biotechnology segment. The company's strong earnings and solid management track record, along with significant opportunities for growth in the life sciences and diagnostic markets, make it an attractive investment opportunity.

Bears say

Danaher is a company that has undergone significant transformation over the past few decades through mergers, acquisitions, and divestitures, now primarily focusing on manufacturing scientific instruments and consumables for the life sciences and diagnostic industries. In recent years, the company has faced challenges, including a decline in respiratory testing revenue and the divestiture of its environmental and applied solutions segment. Despite positive commentary on reshoring and a recovery in biotech funding, there are concerns about the company's ability to rebound in key segments, leading to a negative outlook on the stock. Additionally, there may be potential risks related to the integration of recent acquisitions and a slowdown in overall demand for life science instruments.

Danaher (DHR) has been analyzed by 18 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Danaher (DHR) Forecast

Analysts have given Danaher (DHR) a Buy based on their latest research and market trends.

According to 18 analysts, Danaher (DHR) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $230.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $230.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Danaher (DHR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.